Blog

Sep 14, 2022

Lung cancer pill outperforms chemotherapy in clinical trials

Posted by in category: biotech/medical

Lung cancer is the third most common cancer in the U.S., according to the Centers for Disease Control and Prevention. Patients may be treated by a variety of approved immunotherapies and chemotherapies if surgery is not an option.

An oral pill for lung cancer named Lumakras, made by Amgen, shows promise for lung cancer patients who have tried many other treatments already with little improvement.

In phase 3 clinical trials, patients with non-small cell lung cancer received Lumakras or intravenous chemotherapy (docetaxel). The patients may have tried other treatments like immunotherapy.

Comments are closed.